Skip to main content
رجوع
LEGN logo

Legend Biotech Corporation

جودة البيانات: 100%
LEGN
NASDAQ Healthcare Biotechnology
KWD 17.60
▲ KWD 0.51 (2.98%)
القيمة السوقية: 3.26B
نطاق اليوم
KWD 17.26 KWD 17.82
نطاق 52 أسبوعًا
KWD 16.24 KWD 45.30
حجم التداول
1,102,321
متوسط 50 يوم / 200 يوم
KWD 19.12 / KWD 29.31
الإغلاق السابق
KWD 17.09

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E -10.9 0.3
P/B 3.3 3.0
ROE % -29.1 3.7
Net Margin % -28.9 3.8
Rev Growth 5Y % 96.8 10.0
D/E 0.4 0.2

السعر المستهدف للمحللين

Hold
KWD 58.60 +233.0%
Low: KWD 24.00 High: KWD 75.00
مكرر الربحية المستقبلي
71.64
ربحية السهم المستقبلية
KWD 0.24
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
1.44B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 2.13
KWD 1.80 – KWD 2.44
2.77B 1
FY2029 KWD 1.95
KWD 1.64 – KWD 2.23
2.53B 1
FY2028 KWD 1.72
KWD 1.45 – KWD 1.97
2.12B 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-10 KWD 0.00 -KWD 0.08 -15194.3%
2025-11-12 -KWD 0.13 -KWD 0.11 +15.4%
2025-08-11 -KWD 0.22 -KWD 0.34 -54.5%
2025-05-13 -KWD 0.40 -KWD 0.07 +82.5%
2025-03-11 -KWD 0.39 -KWD 0.15 +61.5%
2024-08-09 -KWD 0.54 -KWD 0.05 +90.7%
2024-05-13 -KWD 0.29 -KWD 0.16 +44.8%
2024-03-11 -KWD 0.70 -KWD 0.40 +42.9%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 96.76% annually over 5 years — strong growth
Debt/Equity of 0.41 — conservative balance sheet
Negative free cash flow of -168.04M
Revenue growth is decelerating — 1Y growth trails 5Y average by 32.29%
Capital efficient — spends only 6.55% of revenue on capex

النمو

Revenue Growth (5Y)
96.76%
Revenue (1Y)64.47%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-29.14%
ROIC-7.25%
Net Margin-28.85%
Op. Margin-13.27%

الأمان

Debt / Equity
0.41
Current Ratio1.96
Interest Coverage-6.38

التقييم

P/E Ratio
-10.94
Forward P/E71.64
P/B Ratio3.25
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 64.47% Revenue Growth (3Y) 90.21%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 96.76% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.03B Net Income (TTM) -297.58M
ROE -29.14% ROA -17.16%
Gross Margin 60.34% Operating Margin -13.27%
Net Margin -28.85% Free Cash Flow (TTM) -168.04M
ROIC -7.25% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.41 Current Ratio 1.96
Interest Coverage -6.38
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10.94 Forward P/E 71.64
P/B Ratio 3.25 P/S Ratio 3.16
PEG Ratio -0.21 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 2.27 Fwd Earnings Yield 1.40%
FCF Yield -5.16%
Market Cap 3.26B Enterprise Value 2.77B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.03B 627.24M 285.14M 117.01M 68.83M
Net Income -297.58M -177.03M -518.25M -446.35M -403.58M
EPS (Diluted) -1.60 -0.97 -2.94 -2.81 -2.74
Gross Profit 622.44M 392.66M 140.93M 51.64M 68.83M
Operating Income -136.86M -303.24M -439.49M -455.62M -392.29M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.73B 1.67B 1.85B 1.33B 1.12B
Total Liabilities 723.60M 629.61M 597.24M 586.65M 353.52M
Shareholders' Equity 1.00B 1.04B 1.25B 744.31M 765.94M
Total Debt 413.70M 350.60M 328.67M 284.53M 122.97M
Cash & Equivalents 901.90M 286.75M 1.28B 786.03M 688.94M
Current Assets 1.25B 1.28B 1.50B 1.10B 949.85M
Current Liabilities 636.40M 277.65M 216.42M 297.79M 229.20M